AR105341A1 - Derivados de etinilo como moduladores metabotrópicos del receptor del glutamato - Google Patents
Derivados de etinilo como moduladores metabotrópicos del receptor del glutamatoInfo
- Publication number
- AR105341A1 AR105341A1 ARP160102117A ARP160102117A AR105341A1 AR 105341 A1 AR105341 A1 AR 105341A1 AR P160102117 A ARP160102117 A AR P160102117A AR P160102117 A ARP160102117 A AR P160102117A AR 105341 A1 AR105341 A1 AR 105341A1
- Authority
- AR
- Argentina
- Prior art keywords
- ethylly
- metabotropic
- modulators
- derivatives
- group
- Prior art date
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal (AREA)
Abstract
La presente solicitud se refiere a compuestos de fórmula (1), en la que: R¹ es alquilo inferior; R² es fenilo o piridinilo, en el que el átomo de N en el grupo piridinilo puede encontrarse en posiciones diferentes; n es 0, 1 ó 2; V / U son, independientemente, O ó CH₂, en los que V y U no pueden ser simultáneamente O; L es un grupo heteroarilo de cinco o seis elementos, seleccionado de entre el grupo de fórmulas (2), o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos. Los compuestos pueden utilizarse para el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo-compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes de tipo 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176854 | 2015-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105341A1 true AR105341A1 (es) | 2017-09-27 |
Family
ID=53758003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102117A AR105341A1 (es) | 2015-07-15 | 2016-07-13 | Derivados de etinilo como moduladores metabotrópicos del receptor del glutamato |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10189848B2 (es) |
| EP (1) | EP3322701B1 (es) |
| JP (1) | JP6761821B2 (es) |
| KR (1) | KR20180026438A (es) |
| CN (1) | CN107580598B (es) |
| AR (1) | AR105341A1 (es) |
| AU (1) | AU2016292863B2 (es) |
| CA (1) | CA2984711C (es) |
| CL (1) | CL2018000036A1 (es) |
| CO (1) | CO2017011174A2 (es) |
| CR (1) | CR20180022A (es) |
| DK (1) | DK3322701T3 (es) |
| ES (1) | ES2733468T3 (es) |
| HR (1) | HRP20191139T1 (es) |
| HU (1) | HUE045145T2 (es) |
| IL (1) | IL255096B (es) |
| LT (1) | LT3322701T (es) |
| MA (1) | MA42442B1 (es) |
| MX (1) | MX2018000592A (es) |
| PE (1) | PE20180356A1 (es) |
| PH (1) | PH12018500106A1 (es) |
| PL (1) | PL3322701T3 (es) |
| PT (1) | PT3322701T (es) |
| RS (1) | RS58929B1 (es) |
| RU (1) | RU2721776C9 (es) |
| SI (1) | SI3322701T1 (es) |
| TR (1) | TR201909160T4 (es) |
| TW (1) | TWI612962B (es) |
| UA (1) | UA120463C2 (es) |
| WO (1) | WO2017009275A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
| HUE045145T2 (hu) | 2015-07-15 | 2019-12-30 | Hoffmann La Roche | Etinil-származékok metabotróp glutamátreceptor-modulátorokként |
| MX2019000442A (es) * | 2016-07-18 | 2019-06-20 | Hoffmann La Roche | Derivados de etinilo. |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
| AU2019309448B2 (en) | 2018-07-26 | 2024-08-29 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての二環式複素環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| KR101333861B1 (ko) * | 2005-05-24 | 2013-11-28 | 메르크 세로노 에스. 에이. | Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체 |
| MX2009002347A (es) | 2006-08-31 | 2009-03-16 | Schering Corp | Derivados de hidantoina utiles como agentes antibacterianos. |
| SG185285A1 (en) | 2007-06-03 | 2012-11-29 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| CA3081694C (en) | 2008-02-01 | 2022-07-26 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
| US8513381B2 (en) | 2009-01-19 | 2013-08-20 | Fondazione Irccs Ca' Granda-Ospedale Maggiore Policlinico | Melanocortin analogs with antimicrobial activity |
| US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| BR112012004919A2 (pt) | 2009-09-04 | 2019-09-24 | Univ Vanderbilt | potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| MX2013011107A (es) | 2011-04-26 | 2013-10-17 | Hoffmann La Roche | Derivados de pirazolidin-3-ona. |
| KR101554803B1 (ko) | 2011-04-26 | 2015-09-21 | 에프. 호프만-라 로슈 아게 | Mglur5의 양성 알로스테릭 조절체로서 에틴일 유도체 |
| AU2012258618B2 (en) | 2011-05-26 | 2017-05-25 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptors 5 modulators and methods of use thereof |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| PL2875000T3 (pl) | 2012-07-17 | 2017-03-31 | F.Hoffmann-La Roche Ag | Pochodne aryloetynylowe |
| CA2879489A1 (en) | 2012-10-18 | 2014-04-24 | F.Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
| PE20150628A1 (es) | 2012-10-18 | 2015-05-11 | Hoffmann La Roche | Derivados de etinilo como moduladores de la actividad del receptor mglur5 |
| WO2014124560A1 (en) | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Mglur regulators |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2015044075A1 (en) * | 2013-09-25 | 2015-04-02 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| WO2015127140A2 (en) | 2014-02-19 | 2015-08-27 | Jody Berry | Marburg monoclonal antibodies |
| PT3110802T (pt) | 2014-02-25 | 2018-12-04 | Hoffmann La Roche | Derivados de etinilo |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CA2963470A1 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| EP3271353B1 (en) | 2015-03-19 | 2019-11-27 | H. Hoffnabb-La Roche Ag | 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4 |
| HUE045145T2 (hu) | 2015-07-15 | 2019-12-30 | Hoffmann La Roche | Etinil-származékok metabotróp glutamátreceptor-modulátorokként |
| MX2019000442A (es) | 2016-07-18 | 2019-06-20 | Hoffmann La Roche | Derivados de etinilo. |
-
2016
- 2016-07-11 HU HUE16739442A patent/HUE045145T2/hu unknown
- 2016-07-11 PT PT16739442T patent/PT3322701T/pt unknown
- 2016-07-11 LT LTEP16739442.8T patent/LT3322701T/lt unknown
- 2016-07-11 KR KR1020187000004A patent/KR20180026438A/ko active IP Right Grant
- 2016-07-11 SI SI201630292T patent/SI3322701T1/sl unknown
- 2016-07-11 UA UAA201801133A patent/UA120463C2/uk unknown
- 2016-07-11 EP EP16739442.8A patent/EP3322701B1/en active Active
- 2016-07-11 WO PCT/EP2016/066393 patent/WO2017009275A1/en active Application Filing
- 2016-07-11 PL PL16739442T patent/PL3322701T3/pl unknown
- 2016-07-11 MA MA42442A patent/MA42442B1/fr unknown
- 2016-07-11 PE PE2017002337A patent/PE20180356A1/es unknown
- 2016-07-11 TR TR2019/09160T patent/TR201909160T4/tr unknown
- 2016-07-11 DK DK16739442.8T patent/DK3322701T3/da active
- 2016-07-11 RU RU2018103944A patent/RU2721776C9/ru active
- 2016-07-11 JP JP2017564709A patent/JP6761821B2/ja active Active
- 2016-07-11 CN CN201680026777.2A patent/CN107580598B/zh active Active
- 2016-07-11 ES ES16739442T patent/ES2733468T3/es active Active
- 2016-07-11 MX MX2018000592A patent/MX2018000592A/es active IP Right Grant
- 2016-07-11 AU AU2016292863A patent/AU2016292863B2/en active Active
- 2016-07-11 RS RS20190819A patent/RS58929B1/sr unknown
- 2016-07-11 CA CA2984711A patent/CA2984711C/en active Active
- 2016-07-11 CR CR20180022A patent/CR20180022A/es unknown
- 2016-07-13 AR ARP160102117A patent/AR105341A1/es unknown
- 2016-07-14 TW TW105122266A patent/TWI612962B/zh active
-
2017
- 2017-10-17 IL IL255096A patent/IL255096B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011174A patent/CO2017011174A2/es unknown
-
2018
- 2018-01-05 CL CL2018000036A patent/CL2018000036A1/es unknown
- 2018-01-12 US US15/869,268 patent/US10189848B2/en active Active
- 2018-01-12 PH PH12018500106A patent/PH12018500106A1/en unknown
- 2018-12-14 US US16/220,512 patent/US11034699B2/en active Active
-
2019
- 2019-06-21 HR HRP20191139TT patent/HRP20191139T1/hr unknown
-
2021
- 2021-05-09 US US17/315,349 patent/US12006323B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105341A1 (es) | Derivados de etinilo como moduladores metabotrópicos del receptor del glutamato | |
| AR099047A1 (es) | Derivados etinilo | |
| AR097721A1 (es) | Derivados de etinilo | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| AR099640A1 (es) | Derivados de pirrolopiridina o pirazolopiridina | |
| AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| AR093042A1 (es) | Derivados de etinilo | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| PH12016502251A1 (en) | Peptides as oxytocin agonists | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
| AR104863A1 (es) | Derivados imidazol | |
| CO2018013824A2 (es) | Derivados de etinilo | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| ECSP13012990A (es) | Derivados de pirazolidin-3-ona | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| AR105327A1 (es) | Derivados de imidazol | |
| UY33722A (es) | Oxazolidinonas como moduladores de mglur5 | |
| CO2017011010A2 (es) | Derivados de etinilo | |
| AR093029A1 (es) | Derivados de etilino | |
| AR107490A1 (es) | Derivados de pirazol-piridina como inhibidores de eaat3 | |
| CO7180198A2 (es) | Ariletinilo pirimidinas | |
| MX2016016190A (es) | Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central. |